Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS-Reference-Cited by-同舟云学术

Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS

Published:2019-01 Issue:1 Volume:201 Page:106-112
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Kearns James T.¹,Faino Anna V.²,Schenk Jeanette M.²,Newcomb Lisa F.¹²,Brooks James D.³,Carroll Peter R.⁴,Dash Atreya¹,Ellis William J.¹,Fabrizio Michael⁵,Gleave Martin E.⁶,Morgan Todd M.⁷,Nelson Peter S.²,Thompson Ian M.⁸,Wagner Andrew⁹,Zheng Yingye²,Lin Daniel W.¹²

Affiliation:

1. Department of Urology, University of Washington School of Medicine, Seattle, Washington

2. Fred Hutchinson Cancer Research Center, Seattle, Washington

3. Stanford University, San Francisco, California

4. University of California-San Francisco, San Francisco, California

5. Eastern Virginia Medical School, Norfolk, Virginia

6. University of British Columbia, Vancouver, British Columbia, Canada

7. University of Michigan, Ann Arbor, Michigan

8. University of Texas Health Sciences Center at San Antonio, San Antonio, Texas

9. Beth Israel Deaconess Medical Center, Boston, Massachusetts

Publisher

Ovid Technologies (Wolters Kluwer Health)